What exactly changed in the BDSX analyst rating on February 27, 2026?

William Blair upgraded Biodesix from **Market Perform** to **Outperform** on **February 27, 2026**. The upgrade did not include a new price target and followed reported revenue strength and margin gains.

How should investors treat the William Blair upgrade for BDSX?

The upgrade is a positive signal for the BDSX analyst rating, reflecting confidence in execution. Investors should weigh the upgrade against profitability risks, recent guidance, and position sizing.

Did William Blair set a new BDSX price target with the upgrade?

No. William Blair upgraded BDSX to Outperform but did not disclose a new price target in the published note accompanying the rating change. Monitor for follow-ups.

How does Meyka view the BDSX analyst rating change?

Meyka AI views the upgrade as a meaningful catalyst and rates BDSX **B+**. This grade reflects benchmark, sector, growth, key metrics, and analyst consensus, but is not investment advice.

Analyst Ratings

William Blair Upgrades BDSX (Biodesix, Inc.) to Outperform Feb 2026

ByHuzaifa Zahoor February 28, 2026February 28, 2026

William Blair upgraded Biodesix, Inc. (BDSX) from Market Perform to Outperform on February 27, 2026. We examine the BDSX analyst rating change, the analyst rationale, and what it means for investors. The upgrade follows strong top-line momentum and margin improvement, and comes alongside fresh guidance for 2026. This note summarizes the upgrade details, quotes the firm’s reasoning, connects the call to Biodesix’s recent results, and flags next steps for shareholders.